Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

[Side effects of methylphenidate in children and the young].

Espadas M, Insa I, Chamorro M, Alda-Diez JA.

Rev Neurol. 2018 Mar 1;66(5):157-162. Review. Spanish.

2.

Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.

Angyal N, Horvath EZ, Tarnok Z, Richman MJ, Bognar E, Lakatos K, Sasvari-Szekely M, Nemoda Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):122-128. doi: 10.1016/j.pnpbp.2018.01.013. Epub 2018 Feb 20.

PMID:
29374517
3.

Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.

Myer NM, Boland JR, Faraone SV.

Mol Psychiatry. 2018 Sep;23(9):1-8. doi: 10.1038/mp.2017.234. Epub 2017 Dec 12.

PMID:
29230023
4.

Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases.

Sundararajan T, Manzardo AM, Butler MG.

Gene. 2018 Jan 30;641:25-34. doi: 10.1016/j.gene.2017.10.035. Epub 2017 Oct 13.

PMID:
29032150
5.

No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.

Geissler JM; International Parkinson Disease Genomics Consortium members, Romanos M, Gerlach M, Berg D, Schulte C.

Atten Defic Hyperact Disord. 2017 Jun;9(2):121-127. doi: 10.1007/s12402-017-0219-8. Epub 2017 Feb 7.

6.

Association of norepinephrine transporter gene polymorphisms in attention-deficit/hyperactivity disorder in Korean population.

Oh SY, Kim YK.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 27. pii: S0278-5846(16)30326-8. doi: 10.1016/j.pnpbp.2016.10.006. [Epub ahead of print]

PMID:
27984158
7.

Investigating the genetic basis of attention to facial expressions: the role of the norepinephrine transporter gene.

Yang X, Ru W, Wang B, Gao X, Yang L, Li S, Xi S, Gong P.

Psychiatr Genet. 2016 Dec;26(6):266-271.

PMID:
27541794
8.

Testing for the mediating role of endophenotypes using molecular genetic data in a twin study of ADHD traits.

Pinto R, Asherson P, Ilott N, Cheung CH, Kuntsi J.

Am J Med Genet B Neuropsychiatr Genet. 2016 Oct;171(7):982-92. doi: 10.1002/ajmg.b.32463. Epub 2016 May 27.

9.

Age-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.

Bradshaw SE, Agster KL, Waterhouse BD, McGaughy JA.

Brain Res. 2016 Jun 15;1641(Pt B):245-57. doi: 10.1016/j.brainres.2016.01.001. Epub 2016 Jan 14.

10.

Attention deficit hyperactivity disorder: genetic association study in a cohort of Spanish children.

Gomez-Sanchez CI, Riveiro-Alvarez R, Soto-Insuga V, Rodrigo M, Tirado-Requero P, Mahillo-Fernandez I, Abad-Santos F, Carballo JJ, Dal-RĂ© R, Ayuso C.

Behav Brain Funct. 2016 Jan 8;12(1):2. doi: 10.1186/s12993-015-0084-6.

11.

Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET.

Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, Gryglewski G, Kautzky A, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Rujescu D, Kasper S, Lanzenberger R.

Hum Brain Mapp. 2016 Mar;37(3):884-95. doi: 10.1002/hbm.23071. Epub 2015 Dec 17.

12.

Predicting Methylphenidate Response in ADHD Using Machine Learning Approaches.

Kim JW, Sharma V, Ryan ND.

Int J Neuropsychopharmacol. 2015 May 10;18(11):pyv052. doi: 10.1093/ijnp/pyv052.

13.

Association of norepinephrine transporter (NET, SLC6A2) genotype with ADHD-related phenotypes: findings of a longitudinal study from birth to adolescence.

Hohmann S, Hohm E, Treutlein J, Blomeyer D, Jennen-Steinmetz C, Schmidt MH, Esser G, Banaschewski T, Brandeis D, Laucht M.

Psychiatry Res. 2015 Apr 30;226(2-3):425-33. doi: 10.1016/j.psychres.2014.12.029. Epub 2014 Dec 27.

PMID:
25724484
14.

A haplotype of the norepinephrine transporter gene (SLC6A2) is associated with visual memory in attention-deficit/hyperactivity disorder.

Shang CY, Chiang HL, Gau SS.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:89-96. doi: 10.1016/j.pnpbp.2014.12.010. Epub 2014 Dec 30.

PMID:
25554436
15.

Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.

Song J, Kim SW, Hong HJ, Lee MG, Lee BW, Choi TK, Lee SH, Yook KH.

Clin Neuropharmacol. 2014 Sep-Oct;37(5):136-41. doi: 10.1097/WNF.0000000000000045.

PMID:
25229170
16.

The possible involvement of genetic variants of NET1 in the etiology of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.

Liu L, Cheng J, Li H, Yang L, Qian Q, Wang Y.

J Child Psychol Psychiatry. 2015 Jan;56(1):58-66. doi: 10.1111/jcpp.12278. Epub 2014 Jun 19.

PMID:
24942521
17.

Family-based association study of ciliary neurotrophic factor receptor and norepinephrine transporter genes in attention-deficit hyperactivity disorder.

Tzang RF, Hsu CD, Liou YJ, Hong CJ, Tsai SJ.

Psychiatr Genet. 2014 Jun;24(3):118-9. doi: 10.1097/YPG.0000000000000027. No abstract available.

PMID:
24565995
18.

Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.

Johnson KA, Barry E, Lambert D, Fitzgerald M, McNicholas F, Kirley A, Gill M, Bellgrove MA, Hawi Z.

J Child Adolesc Psychopharmacol. 2013 Dec;23(10):655-64. doi: 10.1089/cap.2013.0032.

PMID:
24350812
19.

Extracellular norepinephrine clearance by the norepinephrine transporter is required for skeletal homeostasis.

Ma Y, Krueger JJ, Redmon SN, Uppuganti S, Nyman JS, Hahn MK, Elefteriou F.

J Biol Chem. 2013 Oct 18;288(42):30105-13. doi: 10.1074/jbc.M113.481309. Epub 2013 Sep 4.

20.

Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome.

Green EA, Raj V, Shibao CA, Biaggioni I, Black BK, Dupont WD, Robertson D, Raj SR.

J Am Heart Assoc. 2013 Sep 3;2(5):e000395. doi: 10.1161/JAHA.113.000395.

Supplemental Content

Loading ...
Support Center